Unfortunately, CoQ10 has very low aqueous solubility and a relatively high molecular weight, rendering it poorly bioavailable after oral administration. To overcome these limitations, SourceOne utilizes the VESIsorb® delivery system which has been clinically proven to dramatically improve the pharmacokinetic parameters (Cmax, Tmax, and AUC) of CoQ10.
The peer-reviewed journal, Alternative Therapies in Health & Medicine, published a human pharmacokinetic study comparing the VESIsorb® CoQ10 formulation with three marketed "bio-enhanced" CoQ10 formulas. The data of this study as well as a comparison with available published literature shows an unmatched enhancement of CoQ10 bioavailability achieved by the VESIsorb® CoQ10 formulation.
The benefits are unmatched:
- Faster onset, independent of food/fat status.
- Fewer servings required to achieved the desired therapeutic effect.
- Superior loading for smaller and easier to consumer capsules.
- Addressing issues related to poor absorption like age, diet, and gender.
Simply put, this formula delivers unmatched blood plasma levels of CoQ10 in an elegant softgel capsule.
Further, the need for supplementing with CoQ10 has never been greater, especially with the dramatic increase in the number of people taking statin drugs. It is well established that statins lower cholesterol by blocking cholesterol synthesis, but statins also block the body’s natural CoQ10 production and deplete CoQ10 stored in the body. This has resulted in an increased consumer demand for high bioavailable CoQ10 supplementation.